VIMTA LABS LIMITED
Latest filings
Next results: Fri, 30 Oct · Financial Results- Vimta Labs sets Q2 FY27 investor call for October 30 · Board & Shareholder Meetings
- Board meeting set to approve September quarter and half-year results · Results
- RTA compliance certificate for Sep 2026 quarter · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Provides contract research and laboratory testing services to pharmaceutical, food and environmental, and electronics companies. Operations run out of a ~200,000 sq ft Genome Valley lab campus that is ~60% occupied. The pharma contract research arm is delivering consistent year-on-year growth, while the clinical research arm is showing early signs of recovery after prior-year challenges. Biologics contract research and development services were recently launched, with a first customer order already secured, though meaningful P&L contribution is only expected from the third year onwards. Food and environmental testing is under pressure from Middle East trade disruption, with the business pivoting toward domestic clients. Electronics and electrical testing has stabilised after prior leadership issues and benefits from a 15.19% YoY increase in the defence budget. Employees are the largest cost at 28.1% of revenue, followed by materials at 19.8% and other operating expenses at 17.3%.
Scorecard
Measured from the filed financials, judged against its Healthcare Services peers · as of FY24 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from VIMTA LABS LIMITED's filed financials and exchange disclosures
What does VIMTA LABS LIMITED do?
VIMTA LABS LIMITED is a Healthcare Services company listed on NSE and BSE, trading under the symbol VIMTALABS.
Is VIMTA LABS LIMITED profitable?
Yes. Over the trailing twelve months VIMTA LABS LIMITED reported a net profit of ₹61 Cr on revenue of ₹336 Cr.
Does VIMTA LABS LIMITED pay a dividend?
Yes. The dividend yield is 0.19% at the current price. It paid out 11% of its profit as dividend in FY24.
Is VIMTA LABS LIMITED debt-free?
On a net basis, yes. It reported borrowings of ₹12 Cr on its 30 Sept 2024 balance sheet, but holds ₹2.65 Cr more cash than debt.
Is VIMTA LABS LIMITED expensive compared with its peers?
On trailing P/E, VIMTA LABS LIMITED ranks 21 of 63 in Healthcare Services — cheaper than 68% of them, against an industry median of 34.9×. This is a position, not a valuation judgement.
How much does the VIMTA LABS LIMITED share price move in a day?
On a typical session VIMTA LABS LIMITED moves 1.46% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are VIMTA LABS LIMITED's next results?
Financial Results on Fri, 30 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track VIMTA LABS LIMITED's announcements?
Every NSE and BSE filing by VIMTA LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.